Martin Dietrich, MD, PhD, Florida Cancer Specialists & Research Institute

Articles

Risks of Pneumonitis in Unresectable Stage III NSCLC

July 28th 2021

How to differentiate whether a patient with unresectable stage III non–small cell lung cancer develops pneumonitis from chemoradiation or durvalumab, and insight regarding techniques to help manage treatment toxicities.

Durvalumab for Unresectable Stage III NSCLC

July 28th 2021

Chaitali Nangia, MD, of the Patty and George Hoag Cancer Center, reacts to the significance of the 5-year overall survival data for the PACIFIC trial evaluating the use of durvalumab after chemoradiation as treatment for inoperable stage III non–small cell lung cancer.

Second-Line Therapy for Stage IV NSCLC

July 21st 2021

Second-line treatment recommendations for patients with stage IV non–small cell lung cancer who experience disease progression after immunotherapy.

Frontline Treatment of Stage IV NSCLC: What’s Next?

July 21st 2021

Future projections regarding the role of novel I-O therapies as frontline treatment for patients with metastatic non–small cell lung cancer.

Immune-Related Adverse Events in NSCLC

July 14th 2021

Recommendations for managing immune-related adverse events associated with checkpoint inhibitors used to treat stage IV non–small cell lung cancer.

Frontline Treatment of Stage IV NSCLC: Biomarkers

July 14th 2021

Martin Dietrich, MD, PhD, shares his thoughts on PD-L1 status, tumor mutational burden, and other predictive and prognostic biomarkers when making treatment decisions for patients with stage IV non–small cell lung cancer.

Frontline Treatment Decisions for Stage IV NSCLC

July 7th 2021

Considerations for selecting frontline therapy for metastatic non–small cell lung cancer based on various new data and treatment approvals in the field of immunotherapy.

Frontline Treatment of Stage IV NSCLC: IPI/NIVO

July 7th 2021

Neal Edward Ready, MD, PhD, describes which patients with stage IV non–small cell lung cancer may benefit from the combination of ipilimumab and nivolumab in the frontline treatment setting.

Frontline I-O Monotherapy Versus Combination Therapy for PD-L1+ Stage IV NSCLC

June 30th 2021

Drs Roy S. Herbst and Sandip P. Patel comment on patient candidacy for immunotherapy as monotherapy to treat PD-L1+ metastatic non–small cell lung cancer versus chemoimmunotherapy.

Frontline Treatment of PD-L1+ Stage IV NSCLC: Cemiplimab

June 30th 2021

Roy S. Herbst, MD, PhD, of Yale Cancer Center, highlights treatment advances in stage IV non–small cell lung cancer, including cemiplimab as frontline monotherapy based on EMPOWER-Lung 1.

The Future of Lung Cancer Treatment

October 26th 2020

Mesothelioma: A Look at DREAM3R and PrECOG Trial

October 26th 2020

Fundamentals of Mesothelioma

October 26th 2020

Trials in Limited-Stage Small-Cell Lung Cancer

October 26th 2020

Treatment for Progressive Small-Cell Lung Cancer

October 26th 2020

Treatment Options in Small–Cell Lung Cancer

October 26th 2020

Recent Advances in Small-Cell Lung Cancer

October 26th 2020

Treatment for PD-L1 High/Low/Negative Non–Small Cell Lung Cancer

October 26th 2020

Understanding Immune Response in Non–Small Cell Lung Cancer

October 26th 2020

Chemotherapy and Immunotherapy in Non–Small Cell Lung Cancer

October 26th 2020